Charles River Laboratories International (NYSE:CRL) Director James Foster Sells 28,733 Shares of Stock

Posted by George Bondi on Aug 12th, 2026

Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) Director James Foster sold 28,733 shares of the company’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $275.00, for a total transaction of $7,901,575.00. Following the sale, the director directly owned 31,596 shares of the company’s stock, valued at $8,688,900. This represents a 47.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Charles River Laboratories International Price Performance

CRL stock opened at $281.70 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $282.39. The firm has a market cap of $13.45 billion, a P/E ratio of -58.08, a P/E/G ratio of 2.87 and a beta of 1.38. The company’s 50-day moving average price is $218.88 and its two-hundred day moving average price is $189.84.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts anticipate that Charles River Laboratories International, Inc. will post 11.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Madison Asset Management LLC acquired a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at $3,805,000. Great Lakes Advisors LLC bought a new stake in Charles River Laboratories International during the 2nd quarter worth $459,000. Trust Asset Management LLC acquired a new position in Charles River Laboratories International in the 2nd quarter worth about $129,000. Handelsbanken Fonder AB raised its position in Charles River Laboratories International by 36.9% in the second quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company’s stock valued at $4,378,000 after purchasing an additional 5,200 shares during the last quarter. Finally, Czech National Bank raised its position in Charles River Laboratories International by 2.3% in the second quarter. Czech National Bank now owns 13,710 shares of the medical research company’s stock valued at $3,109,000 after purchasing an additional 307 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

CRL has been the topic of several recent analyst reports. Citigroup reiterated a “buy” rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. BNP Paribas Exane set a $250.00 price objective on Charles River Laboratories International in a research report on Wednesday, July 1st. Morgan Stanley raised their price objective on Charles River Laboratories International from $260.00 to $300.00 and gave the company an “overweight” rating in a research note on Friday. Barclays reiterated an “overweight” rating and issued a $300.00 target price on shares of Charles River Laboratories International in a research report on Wednesday, August 5th. Finally, Piper Sandler set a $300.00 target price on Charles River Laboratories International in a research note on Monday. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $255.65.

Read Our Latest Research Report on CRL

Key Charles River Laboratories International News

Here are the key news stories impacting Charles River Laboratories International this week:

Positive Sentiment: Analyst support remains favorable. Piper Sandler set a $300 price target, while Barclays maintained an overweight rating and a $300 target. RBC also raised its target to $282 and reiterated an outperform rating. Overall, 12 analysts rate CRL a Buy, three recommend Hold and one recommends Sell, producing a consensus “Moderate Buy” rating. Charles River Laboratories International Given Consensus Rating of Moderate Buy
Positive Sentiment: Recent operating results exceeded expectations. Charles River reported quarterly adjusted earnings of $3.02 per share versus the $2.77 consensus estimate, while revenue of approximately $1.0 billion topped expectations of $980.5 million. Fiscal 2026 earnings guidance remains $11.15 to $11.45 per share.
Positive Sentiment: Strong momentum has attracted attention. CRL reached a new 52-week high near $277, with trading volume above its average. The stock is also well above its 50-day and 200-day moving averages, indicating continued technical momentum. Charles River Laboratories International Sets New 52-Week High
Neutral Sentiment: International-market exposure remains an investor focus. A recent analysis examines how Charles River’s international revenue trends could affect Wall Street forecasts and the stock’s outlook, but the provided report does not identify a specific estimate change. International Markets and Charles River Deep Dive
Negative Sentiment: Several insiders sold shares. Director James C. Foster sold 28,733 shares for approximately $7.9 million under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 47.6%. EVP Victoria Creamer sold 4,179 shares worth about $1.1 million, and CAO Michael Gunnar Knell sold 6,645 shares worth approximately $1.7 million. These planned transactions may raise caution, although they do not necessarily signal deteriorating business prospects. SEC insider transaction filing

About Charles River Laboratories International

(Get Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.